MEDINDIA
English
हिन्दी
Español
français
中文
Email
3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Methyldopa.
Acebutolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Acebutolol.
Acemetacin
The therapeutic efficacy of Methyldopa can be decreased when used in combination with Acemetacin.
Acepromazine
Acepromazine may decrease the vasoconstricting activities of Methyldopa.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Methyldopa.
Aliskiren
Methyldopa may increase the hypotensive activities of Aliskiren.
Alprenolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Alprenolol.
Ambrisentan
Methyldopa may increase the hypotensive activities of Ambrisentan.
Amifostine
Methyldopa may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Methyldopa may increase the hypotensive activities of Amifostine.
Amiloride
The risk or severity of adverse effects can be increased when Amiloride is combined with Methyldopa.
Amineptin
Amineptine may decrease the antihypertensive activities of Methyldopa.
Amiodarone
Methyldopa may increase the atrioventricular blocking (AV block) activities of Amiodarone.
Amitriptyline
Amitriptyline may decrease the antihypertensive activities of Methyldopa.
Amlodipine
Amlodipine may increase the hypotensive activities of Methyldopa.
Amobarbital
Amobarbital may increase the hypotensive activities of Methyldopa.
Amoxapine
Amoxapine may decrease the antihypertensive activities of Methyldopa.
Amphetamine
The risk or severity of hypertension can be increased when Amphetamine is combined with Methyldopa.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Methyldopa.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Methyldopa.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Methyldopa is combined with Amyl Nitrite.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyldopa.
Apraclonidine
The risk or severity of adverse effects can be increased when Apraclonidine is combined with Methyldopa.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Methyldopa.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Methyldopa.
Asenapine
Methyldopa may increase the atrioventricular blocking (AV block) activities of Asenapine.
Atenolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Atenolol.
Avanafil
Avanafil may increase the antihypertensive activities of Methyldopa.
Azilsartan
The risk or severity of adverse effects can be increased when Methyldopa is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Methyldopa is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Methyldopa is combined with Azilsartan medoxomil.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Methyldopa.
Barbital
Barbital may increase the hypotensive activities of Methyldopa.
Benazepril
Benazepril may increase the hypotensive activities of Methyldopa.
Bendroflumethiazide
Bendroflumethiazide may increase the hypotensive activities of Methyldopa.
Benzylpenicilloyl polylysine
Methyldopa may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
Bepridil
Methyldopa may increase the hypotensive activities of Bepridil.
Beractant
Methyldopa may increase the bradycardic activities of Beractant.
Betaxolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Betaxolol.
Bethanidine
Bethanidine may increase the hypotensive activities of Methyldopa.
Bimatoprost
Bimatoprost may increase the hypotensive activities of Methyldopa.
Bisoprolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
Bopindolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Bopindolol.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Methyldopa.
Bosentan
Bosentan may increase the hypotensive activities of Methyldopa.
Bosentan Anhydrous
Bosentan may increase the hypotensive activities of Methyldopa.
Bretylium
Bretylium may increase the bradycardic activities of Methyldopa.
Brexpiprazole
Brexpiprazole may decrease the vasoconstricting activities of Methyldopa.
Brimonidine
Brimonidine may increase the antihypertensive activities of Methyldopa.
Bromocriptine
Bromocriptine may increase the hypertensive and vasoconstricting activities of Methyldopa.
Bumetanide
The risk or severity of adverse effects can be increased when Bumetanide is combined with Methyldopa.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Methyldopa.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methyldopa.
Bupranolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Bupranolol.
Butriptyline
Butriptyline may decrease the antihypertensive activities of Methyldopa.
Cabergoline
Cabergoline may increase the hypertensive and vasoconstricting activities of Methyldopa.
Cafedrine
Methyldopa may increase the hypotensive activities of Cafedrine.
Calfactant
Methyldopa may increase the bradycardic activities of Calfactant.
Canagliflozin
The risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.
Candesartan
Methyldopa may increase the hypotensive activities of Candesartan.
Candesartan Cilexetil
Candesartan cilexetil may increase the hypotensive activities of Methyldopa.
Captopril
Methyldopa may increase the hypotensive activities of Captopril.
Carteolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Carteolol.
Carvedilol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Carvedilol.
Celiprolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Celiprolol.
Ceritinib
Methyldopa may increase the bradycardic activities of Ceritinib.
Chlorothiazide
Chlorothiazide may increase the hypotensive activities of Methyldopa.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methyldopa.
Chlorthalidone
Chlorthalidone may increase the hypotensive activities of Methyldopa.
Cicletanine
Methyldopa may increase the hypotensive activities of Cicletanine.
Cilazapril
Methyldopa may increase the hypotensive activities of Cilazapril.
Clevidipine
The risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Methyldopa.
Clomipramine
Clomipramine may decrease the antihypertensive activities of Methyldopa.
Clonidine
Clonidine may increase the hypotensive activities of Methyldopa.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Methyldopa.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Methyldopa.
Crizotinib
Methyldopa may increase the bradycardic activities of Crizotinib.
Cryptenamine
Cryptenamine may increase the hypotensive activities of Methyldopa.
Cyclopenthiazide
Methyldopa may increase the hypotensive activities of Cyclopenthiazide.
Cyclothiazide
Cyclothiazide may increase the hypotensive activities of Methyldopa.
Dapagliflozin
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.
Dapiprazole
Dapiprazole may decrease the vasoconstricting activities of Methyldopa.
Debrisoquin
Debrisoquin may increase the hypotensive activities of Methyldopa.
Deserpidine
Methyldopa may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Methyldopa.
Desipramine
Methyldopa may increase the atrioventricular blocking (AV block) activities of Desipramine.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Methyldopa.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methyldopa.
Dextroamphetamine
Dextroamphetamine may decrease the vasoconstricting activities of Methyldopa.
Diazoxide
Diazoxide may increase the hypotensive activities of Methyldopa.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Methyldopa is combined with Diclofenamide.
Digoxin
Digoxin may increase the bradycardic activities of Methyldopa.
Dihydralazine
Dihydralazine may increase the hypotensive activities of Methyldopa.
Dihydroergotamine
Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Methyldopa.
Diltiazem
Diltiazem may increase the hypotensive activities of Methyldopa.
Dinutuximab
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Methyldopa is combined with Dipyridamole.
Donepezil
Donepezil may increase the bradycardic activities of Methyldopa.
Dorzolamide
Dorzolamide may increase the hypotensive activities of Methyldopa.
Dothiepin
Dosulepin may decrease the antihypertensive activities of Methyldopa.
Doxazosin
Doxazosin may decrease the vasoconstricting activities of Methyldopa.
Doxepin
Doxepin may decrease the antihypertensive activities of Methyldopa.
Dronedarone
Methyldopa may increase the bradycardic activities of Dronedarone.
Droperidol
Droperidol may decrease the vasoconstricting activities of Methyldopa.
Duloxetine
Methyldopa may increase the orthostatic hypotensive activities of Duloxetine.
Empagliflozin
The risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.
Enalapril
Enalapril may increase the hypotensive activities of Methyldopa.
Enalaprilat
Methyldopa may increase the hypotensive activities of Enalaprilat.
Enalaprilat Anhydrous
Methyldopa may increase the hypotensive activities of Enalaprilat.
Entacapone
The metabolism of Methyldopa can be decreased when combined with Entacapone.
Epinephrine
Epinephrine may decrease the vasoconstricting activities of Methyldopa.
Eplerenone
The risk or severity of adverse effects can be increased when Eplerenone is combined with Methyldopa.
Epoprostenol
Methyldopa may increase the hypotensive activities of Epoprostenol.
Eprosartan
Eprosartan may increase the hypotensive activities of Methyldopa.
ergoloid mesylates, USP
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Methyldopa.
Ergonovine
Ergonovine may increase the hypertensive and vasoconstricting activities of Methyldopa.
Ergotamine
Ergotamine may increase the hypertensive and vasoconstricting activities of Methyldopa.
Escitalopram
Escitalopram may decrease the vasoconstricting activities of Methyldopa.
Esmolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Esmolol.
Ethacrynate
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methyldopa.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methyldopa.
Felodipine
Methyldopa may increase the hypotensive activities of Felodipine.
Fenoldopam
Fenoldopam may increase the hypotensive activities of Methyldopa.
Ferric Carboxymaltose
The serum concentration of Methyldopa can be decreased when it is combined with Ferric Carboxymaltose.
Ferric Pyrophosphate
The serum concentration of Methyldopa can be decreased when it is combined with Ferric pyrophosphate.
Ferulic Acid
Methyldopa may increase the hypotensive activities of Ferulic acid.
Fingolimod
Methyldopa may increase the bradycardic activities of Fingolimod.
Flupenthixol
Flupentixol may decrease the vasoconstricting activities of Methyldopa.
Fosinopril
Fosinopril may increase the hypotensive activities of Methyldopa.
Fostamatinib
Fostamatinib may increase the antihypertensive activities of Methyldopa.
Furazolidone
The risk or severity of hypertension can be increased when Furazolidone is combined with Methyldopa.
Furosemide
The risk or severity of adverse effects can be increased when Furosemide is combined with Methyldopa.
Galantamine
Galantamine may increase the bradycardic activities of Methyldopa.
Guanabenz
Guanabenz may increase the hypotensive activities of Methyldopa.
Guanadrel
Guanadrel may increase the hypotensive activities of Methyldopa.
Guanethidine
Methyldopa may increase the hypotensive activities of Guanethidine.
Guanfacine
Guanfacine may increase the hypotensive activities of Methyldopa.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Methyldopa.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Methyldopa.
Hyaluronidase
Hyaluronidase may increase the vasoconstricting activities of Methyldopa.
Hyaluronidase, Ovine
Hyaluronidase may increase the vasoconstricting activities of Methyldopa.
Hydralazine
Hydralazine may increase the hypotensive activities of Methyldopa.
Hydrochlorothiazide
Methyldopa may increase the hypotensive activities of Hydrochlorothiazide.
Hydroflumethiazide
Hydroflumethiazide may increase the hypotensive activities of Methyldopa.
Iloperidone
Iloperidone may decrease the vasoconstricting activities of Methyldopa.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Methyldopa.
Imidapril
Methyldopa may increase the hypotensive activities of Imidapril.
Imipramine
Imipramine may decrease the antihypertensive activities of Methyldopa.
Indapamide
Indapamide may increase the hypotensive activities of Methyldopa.
Indoramin
Indoramin may increase the hypotensive activities of Methyldopa.
Iproniazid
The risk or severity of hypertension can be increased when Iproniazid is combined with Methyldopa.
Irbesartan
Methyldopa may increase the hypotensive activities of Irbesartan.
Iron
The serum concentration of Methyldopa can be decreased when it is combined with Iron.
Iron Carbonyl
The serum concentration of Methyldopa can be decreased when it is combined with Iron.
Iron Sucrose
The serum concentration of Methyldopa can be decreased when it is combined with Iron saccharate.
Iron-Dextran Complex
The serum concentration of Methyldopa can be decreased when it is combined with Iron Dextran.
Isocarboxazid
The risk or severity of hypertension can be increased when Isocarboxazid is combined with Methyldopa.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Methyldopa.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Methyldopa.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Methyldopa is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Methyldopa is combined with Isoxsuprine.
Isradipine
Isradipine may increase the hypotensive activities of Methyldopa.
Ivabradine
Methyldopa may increase the bradycardic activities of Ivabradine.
Ketanserin
Ketanserin may increase the hypotensive activities of Methyldopa.
Labetalol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Labetalol.
Lacidipine
Methyldopa may increase the hypotensive activities of Lacidipine.
Lacosamide
Methyldopa may increase the atrioventricular blocking (AV block) activities of Lacosamide.
Lanreotide
Methyldopa may increase the bradycardic activities of Lanreotide.
Latanoprost
Latanoprost may increase the hypotensive activities of Methyldopa.
Lercanidipine
Lercanidipine may increase the hypotensive activities of Methyldopa.
Levobetaxolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Levobetaxolol.
Levobunolol
The risk or severity of adverse effects can be increased when Methyldopa is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methyldopa.
Levodopa
Methyldopa may increase the orthostatic hypotensive activities of Levodopa.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Methyldopa.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Methyldopa.
Lisdexamfetamine
Lisdexamfetamine may decrease the vasoconstricting activities of Methyldopa.
Lisdexamfetamine Dimesylate
Lisdexamfetamine may decrease the vasoconstricting activities of Methyldopa.
Lisinopril
Lisinopril may increase the hypotensive activities of Methyldopa.
Lisinopril Anhydrous
Lisinopril may increase the hypotensive activities of Methyldopa.
Lithium
The risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.
Lithium Cation
The risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium.
Lofexidine
Methyldopa may increase the hypotensive activities of Lofexidine.
Losartan
Losartan may increase the hypotensive activities of Methyldopa.
Lucinactant
Methyldopa may increase the bradycardic activities of Lucinactant.
Macitentan
Methyldopa may increase the hypotensive activities of Macitentan.
Manidipine
Methyldopa may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Mannitol is combined with Methyldopa.
Mecamylamine
Mecamylamine may increase the hypotensive activities of Methyldopa.
MELITRACEN
Melitracen may decrease the antihypertensive activities of Methyldopa.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Methyldopa.
Mepindolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Mepindolol.
Mepirodipine
Methyldopa may increase the antihypertensive activities of Barnidipine.
Methazolamide
The risk or severity of adverse effects can be increased when Methazolamide is combined with Methyldopa.
Methohexital
Methohexital may increase the hypotensive activities of Methyldopa.
Methotrimeprazine
Methotrimeprazine may decrease the vasoconstricting activities of Methyldopa.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa.
Methylene blue
The risk or severity of hypertension can be increased when Methylene blue is combined with Methyldopa.
Methylergonovine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Methyldopa.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Methyldopa.
Metipranolol
Methyldopa may increase the hypotensive activities of Metipranolol.
Metolazone
Metolazone may increase the hypotensive activities of Methyldopa.
Metoprolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Metoprolol.
Metyrosine
Methyldopa may increase the hypotensive activities of Metyrosine.
Mianserin
The therapeutic efficacy of Methyldopa can be decreased when used in combination with Mianserin.
Mibefradil
Methyldopa may increase the hypotensive activities of Mibefradil.
Milnacipran
Milnacipran may increase the tachycardic activities of Methyldopa.
Minaprine
The risk or severity of hypertension can be increased when Minaprine is combined with Methyldopa.
Minoxidil
Minoxidil may increase the hypotensive activities of Methyldopa.
Mirtazapine
Mirtazapine may decrease the antihypertensive activities of Methyldopa.
Moclobemide
The risk or severity of hypertension can be increased when Moclobemide is combined with Methyldopa.
Moexipril
Moexipril may increase the hypotensive activities of Methyldopa.
Molsidomine
Molsidomine may increase the hypotensive activities of Methyldopa.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Methyldopa.
Moxonidine
Moxonidine may increase the hypotensive activities of Methyldopa.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Methyldopa.
Nadolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Nadolol.
Nebivolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Nebivolol.
Nefazodone
Nefazodone may decrease the vasoconstricting activities of Methyldopa.
Nesiritide
The risk or severity of adverse effects can be increased when Methyldopa is combined with Nesiritide.
Nialamide
The risk or severity of hypertension can be increased when Nialamide is combined with Methyldopa.
Nicardipine
Nicardipine may increase the hypotensive activities of Methyldopa.
Nicergoline
Nicergoline may decrease the vasoconstricting activities of Methyldopa.
Nicorandil
Nicorandil may increase the hypotensive activities of Methyldopa.
Nifedipine
The risk or severity of adverse effects can be increased when Methyldopa is combined with Nifedipine.
Nilvadipine
Methyldopa may increase the hypotensive activities of Nilvadipine.
Nimodipine
Nimodipine may increase the hypotensive activities of Methyldopa.
Nisoldipine
Nisoldipine may increase the hypotensive activities of Methyldopa.
Nitrendipine
Methyldopa may increase the hypotensive activities of Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Methyldopa.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Methyldopa.
Nitroprusside
Nitroprusside may increase the hypotensive activities of Methyldopa.
Nortriptyline
Nortriptyline may decrease the antihypertensive activities of Methyldopa.
Obinutuzumab
Methyldopa may increase the hypotensive activities of Obinutuzumab.
Octreotide
Octreotide may increase the bradycardic activities of Methyldopa.
Olanzapine
Olanzapine may decrease the vasoconstricting activities of Methyldopa.
Olmesartan
Olmesartan may increase the hypotensive activities of Methyldopa.
Opipramol
Opipramol may decrease the antihypertensive activities of Methyldopa.
Oxprenolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyldopa.
Paliperidone
Paliperidone may decrease the vasoconstricting activities of Methyldopa.
Papaverine
The risk or severity of adverse effects can be increased when Methyldopa is combined with Papaverine.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Methyldopa.
Pargyline
The risk or severity of hypertension can be increased when Pargyline is combined with Methyldopa.
Pasireotide
Methyldopa may increase the bradycardic activities of Pasireotide.
Penbutolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Penbutolol.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Methyldopa.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Methyldopa.
Periciazine
Propericiazine may decrease the vasoconstricting activities of Methyldopa.
Perindopril
Perindopril may increase the hypotensive activities of Methyldopa.
Phenelzine
The risk or severity of hypertension can be increased when Phenelzine is combined with Methyldopa.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Methyldopa.
Phenoxybenzamine
Phenoxybenzamine may increase the hypotensive activities of Methyldopa.
Phentolamine
Phentolamine may increase the hypotensive activities of Methyldopa.
Phentolamine Mesylate
Phentolamine may increase the hypotensive activities of Methyldopa.
Pinacidil
Pinacidil may increase the hypotensive activities of Methyldopa.
Pindolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Methyldopa.
Pizotyline
Pizotifen may decrease the vasoconstricting activities of Methyldopa.
Polythiazide
Methyldopa may increase the hypotensive activities of Polythiazide.
Poractant alfa
Methyldopa may increase the bradycardic activities of Poractant alfa.
Practolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Practolol.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Methyldopa.
Prazosin
Prazosin may decrease the vasoconstricting activities of Methyldopa.
Primidone
Primidone may increase the hypotensive activities of Methyldopa.
Procaine
The risk or severity of hypertension can be increased when Procaine is combined with Methyldopa.
Procarbazine
The risk or severity of hypertension can be increased when Procarbazine is combined with Methyldopa.
Promazine
Promazine may decrease the vasoconstricting activities of Methyldopa.
Propafenone
Methyldopa may increase the atrioventricular blocking (AV block) activities of Propafenone.
Propiomazine
Propiomazine may decrease the vasoconstricting activities of Methyldopa.
Propiverine
Propiverine may decrease the vasoconstricting activities of Methyldopa.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Methyldopa.
Propranolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Propranolol.
Protriptyline
Protriptyline may decrease the antihypertensive activities of Methyldopa.
Quetiapine
The risk or severity of adverse effects can be increased when Methyldopa is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Methyldopa is combined with Quetiapine.
Quinapril
Quinapril may increase the hypotensive activities of Methyldopa.
Quinidine
Quinidine may decrease the vasoconstricting activities of Methyldopa.
Quinine
Quinine may increase the hypotensive activities of Methyldopa.
Racepinephrine
Racepinephrine may decrease the vasoconstricting activities of Methyldopa.
Ramipril
Ramipril may increase the hypotensive activities of Methyldopa.
Rasagiline
The risk or severity of hypertension can be increased when Rasagiline is combined with Methyldopa.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Methyldopa.
Rescinnamine
Methyldopa may increase the hypotensive activities of Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Methyldopa.
Rilmenidine
Rilmenidine may increase the hypotensive activities of Methyldopa.
Riociguat
Methyldopa may increase the hypotensive activities of Riociguat.
Risperidone
Methyldopa may increase the hypotensive activities of Risperidone.
Rituximab
Methyldopa may increase the hypotensive activities of Rituximab.
Rivastigmine
Methyldopa may increase the bradycardic activities of Rivastigmine.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Methyldopa.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methyldopa.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Methyldopa.
Ruxolitinib
Ruxolitinib may increase the bradycardic activities of Methyldopa.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Methyldopa.
Secobarbital
Secobarbital may increase the hypotensive activities of Methyldopa.
Selegiline
The risk or severity of hypertension can be increased when Selegiline is combined with Methyldopa.
Selexipag
Methyldopa may increase the hypotensive activities of Selexipag.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Methyldopa.
Sildenafil
Sildenafil may increase the antihypertensive activities of Methyldopa.
Silodosin
Silodosin may decrease the vasoconstricting activities of Methyldopa.
Sotalol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Sotalol.
Spirapril
Methyldopa may increase the hypotensive activities of Spirapril.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Methyldopa.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyldopa.
Sucroferric Oxyhydroxide
The serum concentration of Methyldopa can be decreased when it is combined with Iron saccharate.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Methyldopa.
Tadalafil
Tadalafil may increase the antihypertensive activities of Methyldopa.
Talinolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Talinolol.
Tamsulosin
Tamsulosin may decrease the vasoconstricting activities of Methyldopa.
Telmisartan
Telmisartan may increase the hypotensive activities of Methyldopa.
Terazosin
Terazosin may decrease the vasoconstricting activities of Methyldopa.
Terbutaline
Methyldopa may increase the atrioventricular blocking (AV block) activities of Terbutaline.
Terbutaline Sulfate
Methyldopa may increase the atrioventricular blocking (AV block) activities of Terbutaline.
Terlipressin
Methyldopa may increase the hypotensive activities of Terlipressin.
Tertatolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Tertatolol.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Methyldopa.
Theodrenaline
Methyldopa may increase the hypotensive activities of Theodrenaline.
Theophylline
Theophylline may increase the antihypertensive activities of Methyldopa.
Theophylline anhydrous
Theophylline may increase the antihypertensive activities of Methyldopa.
Thiamylal
Thiamylal may increase the hypotensive activities of Methyldopa.
Thiopental
Thiopental may increase the hypotensive activities of Methyldopa.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Methyldopa.
Thioproperazine
Thioproperazine may decrease the vasoconstricting activities of Methyldopa.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Methyldopa.
Tianeptine
Tianeptine may decrease the antihypertensive activities of Methyldopa.
Tibolone
Methyldopa may increase the hypotensive activities of Tibolone.
Timolol
Methyldopa may increase the atrioventricular blocking (AV block) activities of Timolol.
Timolol Anhydrous
Methyldopa may increase the atrioventricular blocking (AV block) activities of Timolol.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Methyldopa.
Tofacitinib
Tofacitinib may increase the bradycardic activities of Methyldopa.
Tolazoline
Tolazoline may increase the hypotensive activities of Methyldopa.
Tolcapone
The metabolism of Methyldopa can be decreased when combined with Tolcapone.
Toloxatone
The risk or severity of hypertension can be increased when Toloxatone is combined with Methyldopa.
Torsemide
Torasemide may increase the hypotensive activities of Methyldopa.
Trandolapril
Trandolapril may increase the hypotensive activities of Methyldopa.
Tranylcypromine
The risk or severity of hypertension can be increased when Tranylcypromine is combined with Methyldopa.
Travoprost
Travoprost may increase the hypotensive activities of Methyldopa.
Trazodone
Trazodone may decrease the vasoconstricting activities of Methyldopa.
Treprostinil
Treprostinil may increase the hypotensive activities of Methyldopa.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Methyldopa.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Methyldopa.
Trichlormethiazide
Methyldopa may increase the hypotensive activities of Trichlormethiazide.
Trifluoperazine
Trifluoperazine may decrease the vasoconstricting activities of Methyldopa.
Trimethaphan
Trimethaphan may increase the hypotensive activities of Methyldopa.
Trimipramine
Trimipramine may decrease the antihypertensive activities of Methyldopa.
UNOPROSTONE
Methyldopa may increase the hypotensive activities of Unoprostone.
Urapidil
Urapidil may decrease the vasoconstricting activities of Methyldopa.
Valsartan
Valsartan may increase the hypotensive activities of Methyldopa.
Vardenafil
Vardenafil may increase the antihypertensive activities of Methyldopa.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Methyldopa.
Verapamil
The risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa.
Vincamine
Methyldopa may increase the hypotensive activities of Vincamine.
Vinpocetine
Methyldopa may increase the hypotensive activities of Vinpocetine.
Xylometazoline
Methyldopa may increase the hypotensive activities of Xylometazoline.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Methyldopa.
Ziprasidone
Ziprasidone may decrease the vasoconstricting activities of Methyldopa.
Zofenopril
Methyldopa may increase the hypotensive activities of Zofenopril.
Zuclopenthixol
Zuclopenthixol may decrease the vasoconstricting activities of Methyldopa.
